Moberg Pharma secures US patent for MOB-015 dosing regimen
The United States Patent and Trademark Office has granted Moberg Pharma a patent for a new dosing method for its nail fungus treatment, MOB-015.
Stockholm-based Moberg Pharma has received a patent from the United States Patent and Trademark Office (USPTO) covering an improved dosing regimen for MOB-015, its topical treatment for onychomycosis. The U.S. marks the first region where this specific patent application has been approved.
The patent is based on clinical trial data, including studies that previously supported European regulatory approval, as well as the company’s most recently completed phase studies. By securing this patent, the company expands its intellectual property protection in the competitive field of nail fungus treatments.
This development serves as a key milestone for Moberg Pharma’s commercialization efforts in the U.S. The patent provides the company with legal exclusivity regarding its new dosing approach, which is intended to optimize therapeutic outcomes for patients.